转移性去势抵抗性前列腺癌中CTC与tdEV的自动化计数及表型特征分析
本研究对170例起始新型雄激素受体信号抑制剂(ARSi)治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,利用图像分析工具重新分析既往CellSearch图像,自动化计数CTC与tdEV并量化CTC表型多样性(Shannon指数)。结果显示自动化CTC计数与人工计数预后评估价值相似,且基线CTC表型高异质性与更短的无进展生存和总生存相关。
要点
- 自动化CTC计数与人工计数在mCRPC预后评估中价值相当。
- 基线CTC表型高异质性与更短PFS和OS相关,不受CTC水平影响。
- 基线Shannon指数的预后价值在多变量分析中被化疗状态、CTC计数和PSA水平削弱。
核心结论
- 自动化CTC计数可替代人工计数用于mCRPC预后评估。
- CTC表型多样性是潜在的预后生物标志物,值得进一步研究。
研究设计与样本
- 前瞻性多中心临床研究的回顾性图像再分析,纳入170例起始新线ARSi治疗的mCRPC患者。
- 使用图像分析工具重新分析既往CellSearch图像,检测并计数CTC和tdEV。
主要发现
- 自动化CTC计数与人工计数的临床预后评估价值相似。
- 基线CTC表型高异质性患者的中位PFS为4.82个月,低异质性为8.49个月(HR 1.79;P=0.03)。
- 基线CTC表型高异质性患者的中位OS为12.6个月,低异质性未达到(HR 2.32;P=0.03)。
- 多变量分析显示基线Shannon指数的预后价值被化疗状态、CTC计数和PSA水平削弱。
临床怎么用
- 自动化CTC计数可作为mCRPC预后评估的可靠替代方法。
- CTC表型多样性分析可能为患者预后分层提供额外信息,但需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although most patients with metastatic castration-resistant prostate cancer (mCRPC) initially benefit from treatment with androgen receptor signaling inhibitors (ARSi), resistance inevitably occurs. Hence, we investigated the prognostic value of automated circulating tumor cell (CTC) and tumor-derived extracellular vesicle (tdEV) enumeration and their dynamics, in patients with mCRPC in the context of the initiation of treatment with ARSi. Furthermore, we hypothesize that CTC phenotypic heterogeneity might serve as a measurable biomarker under these circumstances. METHODS: Using an image analysis tool, we reanalyzed all CellSearch images previously acquired in the context of a prospective, multicenter clinical study for patients with mCRPC (n = 170) starting a new line of ARSi, for CTC and tdEV detection and enumeration. CTC (n = 19 129) phenotypic diversity was quantified by the Shannon index (SI). Progression-free survival (PFS) and overall survival (OS) were compared between groups of patients stratified according to CTC, tdEV, and SI levels. RESULTS: Automated CTC enumeration provided similar clinical prognostication compared with operator-based counts. Patients demonstrating high CTC phenotypic heterogeneity before therapy had a shorter median PFS (4.82 vs. 8.49 months, HR 1.79; P = 0.03) and OS (12.6 months vs. not reached, HR 2.32; P = 0.03), compared to patients with low diversity, irrespective of CTC level. Multivariable analysis showed how the prognostic value of the baseline SI was lost by pretreatment chemotherapy status, CTC counts, and PSA levels. CONCLUSIONS: Automated CTC counts are a reliable substitute for reviewer-based enumeration, as they are equally informative for prognosis assessment in patients with mCRPC. Beyond enumeration, we demonstrated the added value of studying CTC phenotypic diversity for patient prognostication, warranting future investigation.
引用
- Oeyen S, Liégeois V, De Laere B, et al. Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020. PMID: 33230201. doi:10.1038/s41391-020-00304-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。